CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
释放 CAR-T 细胞潜能：肌苷诱导的干性与增强的效力
英文原题：Unlocking CAR T cell potential: Inosine-induced stemness and enhanced potency.
查看英文原题
Unlocking CAR T cell potential: Inosine-induced stemness and enhanced potency.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
腺苷（Ado）会驱动肿瘤微环境中的免疫抑制。本期《Cancer Cell》中，Klysz 等人研究了 Ado 介导的免疫抑制。过表达腺苷脱氨酶（ADA-OE）可将 Ado 代谢为肌苷（INO），从而诱导干性并改善 CAR-T 细胞功能。同样，暴露于 INO 也能增强 CAR-T 细胞功能并诱导干性特征。
展开英文摘要原文
Adenosine (Ado) drives immune suppression in the tumor microenvironment. In this issue of Cancer Cell, Klysz et al. investigate Ado-mediated immunosuppression. Overexpression of Ado deaminase (ADA-OE), metabolizing Ado to inosine (INO), induces stemness and improves CAR T cell functionality. Likewise, exposure to INO enhances CAR T cells' function and induces stemness features.
论文信息
- 作者
- Zhang X、Wang H
- 第一作者单位
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 100101 Beijing, China.China
- 通讯作者单位
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 100101 Beijing, China; University of Chinese Academy of Sciences, 100049 Beijing, China; Beijing Institute for Stem Cell and Regenerative Medicine, Beijing 100101, China. Electronic address: wanghaoyi@ioz.ac.cn.China
- 文献类型
- 评论
- 期刊
- Cancer cell2024 Feb 12
- 原文标识
- PubMed 38278148 · DOI 10.1016/j.ccell.2024.01.003